Phase I study of histone deacetylase inhibitor (HDI) MS-275 in adults with refractory or relapsed hematologic malignancies.

被引：0
|
作者：
Gojo, I
Karp, JE
Mann, D
Rollins, S
Greer, J
Tidwell, ML
Zhai, SP
Figg, WD
Trepel, J
Ryan, Q
Sausville, E
机构：
[1] Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA
[2] NCI, Bethesda, MD 20892 USA
来源：
BLOOD | 2002年 / 100卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2198
引用
收藏
页码：559A / 559A
页数：1
相关论文
共 50 条
  • [21] The Class I Histone Deacetylase Inhibitor MS-275 Prevents Pancreatic Beta Cell Death Induced by Palmitate
    Plaisance, Valerie
    Rolland, Laure
    Gmyr, Valery
    Annicotte, Jean-Sebastien
    Kerr-Conte, Julie
    Pattou, Francois
    Abderrahmani, Amar
    JOURNAL OF DIABETES RESEARCH, 2014, 2014
  • [22] A phase I/II study of intravenous LBH589, a novel histone deacetylase (HDAC) inhibitor, in patients (pts) with advanced hematologic malignancies.
    Giles, FJ
    Fischer, T
    Cortes, J
    Beck, J
    Ravandi-Kashani, F
    Garcia-Manero, G
    Kantarjian, HM
    Peng, B
    Rae, PE
    Laird, G
    Sharma, S
    Dugan, M
    Albitar, M
    Bhalla, KM
    BLOOD, 2004, 104 (11) : 499A - 499A
  • [23] A phase I study of panobinostat in children with relapsed and refractory hematologic malignancies
    Goldberg, John
    Bender, Julia
    Jeha, Sima
    Sulis, Maria Luisa
    Gardner, Rebecca
    Pollard, Jessica
    Aquino, Victor
    Laetsch, Theodore
    Winick, Naomi
    Fu, Cecilia
    Marcus, Leigh
    Sun, Weili
    Verma, Anupam
    Burke, Michael
    Ho, Phoenix
    Manley, Thomas
    Mody, Rajen
    Tcheng, Wendy
    Thomson, Blythe
    Park, Julie
    Sposto, Richard
    Messinger, Yoav
    Hijiya, Nobuko
    Gaynon, Paul
    Barredo, Julio
    PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2020, 37 (06) : 465 - 474
  • [24] MS-275, AN HISTONE DEACETYLASE INHIBITOR, REDUCES THE INFLAMMATORY REACTION IN RAT EXPERIMENTAL AUTOIMMUNE NEURITIS
    Zhang, Z. Y.
    Zhang, Z.
    Schluesener, H. J.
    NEUROSCIENCE, 2010, 169 (01) : 370 - 377
  • [25] Phase I study of Triapine®, a novel ribonucleotide reductase inhibitor (RRI), in patients with refractory hematologic malignancies.
    Alvarado, Y
    Brown, R
    DiPersio, J
    Verstovsek, S
    Cortes, J
    O'Brien, S
    Sznol, M
    Kantarjian, H
    Fracasso, P
    Giles, F
    BLOOD, 2002, 100 (11) : 767A - 767A
  • [26] Factors affecting the pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with cancer
    Milin R. Acharya
    Judith E. Karp
    Edward A. Sausville
    Kyunghwa Hwang
    Qin Ryan
    Ivana Gojo
    Jűrgen Venitz
    William D. Figg
    Alex Sparreboom
    Investigational New Drugs, 2006, 24 : 367 - 375
  • [27] Factors affecting the pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with cancer
    Acharya, Milin R.
    Karp, Judith E.
    Sausville, Edward A.
    Hwang, Kyunghwa
    Ryan, Qin
    Gojo, Ivana
    Venitz, Jurgen
    Figg, William D.
    Sparreboom, Alex
    INVESTIGATIONAL NEW DRUGS, 2006, 24 (05) : 367 - 375
  • [28] Treatment with the histone deacetylase inhibitor MS-275 induces Changes in tumor metabolism in hepatoma cells
    Altmann, A.
    Bauder-Wuest, U.
    Strauss, L. G.
    Dimitrakopoulou-Strauss, A.
    Hess-Stumpp, H.
    Eisenhut, M.
    Haberkorn, U.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2005, 32 : S248 - S249
  • [29] Class I histone deacetylase inhibitor MS-275 attenuates vasoconstriction and inflammation in angiotensin II-induced hypertension
    Ryu, Yuhee
    Kee, Hae Jin
    Sun, Simei
    Seok, Young Mi
    Choi, Sin Young
    Kim, Gwi Ran
    Kee, Seung-Jung
    Pflieger, Marc
    Kurz, Thomas
    Kim, Hyung-Seok
    Jeong, Myung Ho
    PLOS ONE, 2019, 14 (03):
  • [30] A phase II multicenter study on the histone deacetylase (HDAC) inhibitor MS-275, comparing two dosage schedules in metastatic melanoma.
    Hauschild, A.
    Trefzer, U.
    Garbe, C.
    Kaehler, K.
    Ugurel, S.
    Kiecker, F.
    Eigentler, T.
    Krissel, H.
    Schadendorf, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 463S - 463S
12345